MACH7

ASX Announcement

14 December 2023

Mach7 signs A$10.2m, 5-year renewal with Sentara Healthcare

- **Sentara Healthcare renews five-year subscription agreement for Enterprise Imaging Platform and eUnity Diagnostic Viewer**
- **ARR doubles under new agreement to approximately A$2.0m for Total Contract Value of A$10.2m**

Mach7 Technologies Limited ("**M7T**" or "the **Company**") (ASX:M7T) today announces it has signed a new 5-year subscription agreement with Sentara Healthcare for its Enterprise Imaging Platform and eUnity Diagnostic Viewer.

Sentara Healthcare is one of the largest health systems in the Mid-Atlantic and Southeast of the United States. It is among the top 20 largest not-for-profit integrated health systems in the country with 30,000 employees and 12 hospitals in Virginia and Northeastern North Carolina.

The agreement is for a five-year subscription license with a minimum fixed fee. The total minimum value of the renewal is A$10.2m and will generate Annual Recurring Revenue (ARR) of approximately A$2.0m. This represents an additional A$1.0m in ARR compared to the current contract with the new agreement effective 1 January 2024. This contract offers further upside should volume continue to exceed current contract minimums.

CEO of Mach7 Mike Lampron said: "Sentara has been a long-standing client of Mach7 and this renewal once again highlights the sticky nature of our customer base. Our continued partnership shows the value of building lasting relationships and our success in providing solutions to complex workflows which involve multiple hospitals, locations and care settings. We are pleased to continue to offer products that make a difference to Sentara Healthcare's capabilities to provide the best healthcare possible in the Virginia and North Carolina region. Our pipeline remains strong and reflects opportunities across multiple geographies and product combinations."

Released on authority of the Board by:

Mike Lampron
Managing Director and Chief Executive Officer

For more information, contact:

Investor Relations
Françoise Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T), founded in 2007, is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organizations. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7's Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. In July 2020, Mach7 acquired Client Outlook and the eUnity Enterprise Diagnostic Viewing technology to augment Mach7's Enterprise Data Management and Departmental Workflow applications. eUnity is a zero-footprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This offers healthcare professionals consolidated access to all patient images and data, ensuring clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the company also gives customers independence to deploy its solutions either on a component basis or in a unified comprehensive platform. With more than 165 customers across 15 different countries, Mach7 has built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit Mach7t.com.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.